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Abstract: Obstructive sleep apnea (OSA) is independently associated with cardiovascular and 
cardiometabolic risk in several large epidemiologic studies. OSA leads to several physiologic 
disturbances such as intermittent hypoxia, sleep fragmentation, and increase in autonomic tone. 
These disturbances have been associated with insulin resistance and type 2 diabetes mellitus 
(T2DM) in animal and human studies. Studies also suggest a bidirectional relationship between 
OSA and T2DM whereby T2DM itself might contribute to the features of OSA. Moreover, 
successful treatment of OSA may reduce these risks, although this is controversial. The purpose 
of this article is to review 1) the links and bidirectional associations between OSA and T2DM; 
2) the pathogenic mechanisms that might link these two disease states; 3) the role of continuous 
positive airway pressure therapy in improving glucose tolerance, sensitivity, and resistance; 
and 4) the implications for clinical practice.
Keywords: Insulin resistance, metabolic syndrome, sleep disordered breathing, intermittent 
hypoxia
Introduction
Obstructive sleep apnea (OSA) is a growing medical problem, with moderate-to-severe 
cases affecting 10%–17% of men and 3%–9% of women between the ages of 30 years 
and 70 years.1 OSA is characterized by repeated upper airway occlusions during sleep 
that result in specific physiologic perturbations, including sleep fragmentation and 
chronic intermittent hypoxia (CIH). These disturbances can lead to a cascade of events 
related to the activation of the sympathoadrenal system, oxidative stress, systemic 
inflammation, and changes in adipokines – all of which can be important in increasing the 
risk of cardiovascular disease, hypertension, metabolic syndrome, and diabetes.2–4 The 
present review will focus on the associations and pathophysiologic mechanisms that link 
OSA with the development of type 2 diabetes mellitus (T2DM).
Epidemiological links between OSA and T2DM
Prevalence of T2DM in patients with OSA
Several large-scale, cross-sectional, and epidemiological studies have suggested that 
OSA is an independent risk factor for the development of T2DM, and that as many 
as 15%–30% of patients with OSA have this comorbidity.5 Moreover, as the severity 
of OSA increases, so does the likelihood T2DM incidence and of worse glycemic 
control in patients with T2DM.6
The Sleep Health Heart Study (SHHS) was a large, prospective cohort study designed 
to investigate the role of OSA as a risk factor for the development of  cardiovascular 
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and other chronic diseases.7 This study provided evidence of 
an independent association between OSA severity and both 
impaired glucose tolerance and insulin resistance. OSA sever-
ity was measured by the apnea–hypopnea index (AHI), which 
reflects the number of apneas/hypopneas per hour of sleep and 
whereby AHI ,5/h is considered normal, AHI 5–15/h is mild, 
AHI 15–29/h is moderate, and AHI .30/h is severe. Impaired 
glucose tolerance was defined as a fasting plasma glucose level 
of 110–125 mg/dL and a 2-hour oral glucose tolerance test 
(OGTT) between 140 mg/dL and 200 mg/dL. After adjust-
ment for multiple potential confounders, including age, body 
mass index (BMI), waist circumference, and self-reported 
sleep duration, subjects with mild- or moderate-to-severe 
OSA had odds ratios (ORs) of 1.27 (95% confidence interval 
[CI] 0.98–1.64) and 1.46 (95% CI 1.09–1.97), respectively, 
for impaired glucose tolerance compared with subjects with 
normal AHIs. The severity of nocturnal hypoxemia was also 
independently associated with glucose intolerance. In addi-
tion, OSA severity was associated with increased insulin 
resistance, which was measured by the homeostasis model 
assessment insulin resistance (HOMA-IR) index.7
The Wisconsin Sleep Cohort was another large, prospec-
tive study that found a significant correlation between the 
severity of OSA and the prevalence of diabetes: 2.8% of 
subjects with an AHI of ,5/h had the diagnosis of diabetes, 
compared to 14.7% of subjects with an AHI of $15/h. The 
OR for the diagnosis of diabetes was 2.30 (95% CI 1.28–4.11; 
P=0.005) in subjects with an AHI of $15/h, compared with 
subjects with an AHI of ,5/h, after adjustment for age, sex, 
and body habitus. On the other hand, a 4-year longitudinal 
analysis of 978 participants without diabetes at entry did not 
demonstrate a statistically significant association of diabetes 
incidence with severity of OSA at baseline, after adjustment 
for potential confounders at the end of the 4-year period.8
The findings of the Busselton Health Study also noted 
an association between OSA and higher T2DM prevalence 
over a 4-year follow-up period. After adjustment for age, 
sex, BMI, waist circumference, HDL cholesterol, and mean 
arterial pressure, moderate-to-severe OSA was found to be 
an independent risk factor for 4-year incident diabetes (OR 
13.45, 95% CI 1.59–114.11) and a univariate risk factor for 
prevalent diabetes (OR 4.37, 95% CI 1.12–17.12).9
Prevalence of OSA in subjects  
with T2DM
The studies described previously demonstrated independent 
associations of OSA with insulin resistance and T2DM. 
Conversely, studies assessing the prevalence of OSA in 
patients with existing T2DM have found remarkably high 
rates of OSA.5,10,11 These findings have raised the possibil-
ity of T2DM as a risk factor for the development of OSA 
in a bidirectional fashion. The prevalence of OSA in obese 
subjects with T2DM was assessed with ambulatory nocturnal 
respiratory monitoring in The Sleep Action for Health in 
Diabetes (AHEAD) study, a four-site ancillary study of the 
Look AHEAD Trial. This is a 16-center trial investigating 
the long-term health impact of lifestyle intervention designed 
to achieve and maintain weight loss in over 5,000 obese 
adults with type 2 diabetes. Sleep testing was performed in 
306 participants in the Sleep AHEAD study; surprisingly, 
86.6% of obese subjects with type 2 diabetes in this study had 
an AHI indicative of sleep apnea (AHI $5/h). The mean AHI 
in this cohort was in the moderate range at 20.5±16.8/h. Of 
these patients, 30.5% had moderate OSA (AHI 15–29/h) and 
22.6% had severe OSA (AHI $30/h). Severe OSA was most 
likely as BMI increased (OR 1.1; 95% CI 1.0–1.2; P=0.03).10 
These findings could be secondary to the common risk factor 
for obesity but also raise the possibility that T2DM might 
contribute to OSA, as will be discussed in future sections.
Association of OSA with metabolic 
syndrome
OSA is closely associated with metabolic syndrome because 
of shared risk factors. The term “Syndrome Z” has been 
developed to describe the links between obesity, insulin resis-
tance, hypertension, and dyslipidemia with OSA. The OR for 
the presence of metabolic syndrome in patients with OSA 
ranges from fivefold to as high as ninefold, when compared 
to subjects without OSA, independent of age and BMI.12–14 
In a Chinese population-based study of 255 subjects, sever-
ity of OSA correlated with an increasing prevalence of the 
metabolic syndrome.14 A Japanese case-control study ana-
lyzed lean men of normal BMI with and without OSA and 
demonstrated an association of OSA with the following three 
components of the metabolic syndrome: insulin resistance, 
hypertension, and dyslipidemia.15 Although it is difficult to 
exclude obesity as major contributing factor for the associa-
tion of OSA with metabolic syndrome, these studies provide 
evidence that factors other than obesity may mediate this 
relationship. Some of these potential mediators are discussed 
in the following sections.
Associations of OSA with nonalcoholic 
fatty liver disease and insulin resistance
Another clinical condition that is closely linked with the 
metabolic syndrome is nonalcoholic fatty liver disease 
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(NAFLD), a common liver disease characterized by exces-
sive fatty deposits in the liver. NAFLD is closely related 
to insulin resistance and has also been recently associated 
with OSA. The CIH induced by OSA can result in structural 
damage to the liver with subsequent hepatic fibrosis and 
inflammation.16–19 These changes appear to be independent of 
obesity since they are seen among both obese and nonobese 
patients with OSA.18 Moreover, there is an independent 
association between the severity of the nocturnal hypoxemia 
and steatosis that is exacerbated by preexisting obesity. These 
results were subsequently confirmed in pediatric patients 
with OSA.20
Potential pathogenic mechanisms 
linking OSA to insulin resistance 
and T2DM
OSA can lead to insulin resistance and pancreatic β-cell 
dysfunction through many intermediary pathways. The 
upper airway occlusion during sleep that is characteristic 
of OSA can be partial, resulting in hypopneas, or complete, 
resulting in apneas. These disordered breathing events result 
in several pathophysiological perturbations, including sleep 
fragmentation, activation of the autonomic system, and 
CIH21,22 (see Figure 1).
Sleep fragmentation
Sleep fragmentation in the face of normal sleep duration is 
a common consequence of OSA and results from frequent 
arousals that often occur at the termination of sleep-disordered 
breathing events. These are detected on the cortical electro-
encephalogram and can contribute to elevated sympathetic 
activity and the symptom of daytime somnolence, which is a 
characteristic clinical feature of OSA.23 Sleep deprivation and 
fragmentation are likely risk factors for obesity via effects on 
metabolism and inflammation. Sleep fragmentation associ-
ated with OSA most likely also plays an important role in the 
development of insulin resistance in many of these patients. 
Exposing human subjects to acute sleep fragmentation was 
shown to decrease insulin sensitivity.24,25 A recent animal 
study also found decreases in visceral and adipose cell insu-
lin sensitivity in mice that were exposed to sleep disruption 
during their natural sleep period. Importantly, this study 
also provided a potential mechanistic link between sleep 
fragmentation and insulin resistance. It posited that sleep 
fragmentation reduced insulin sensitivity through observed 
increases in macrophage number and infiltration in visceral 
fat along with increases in Nox2 (nicotinamide adenine 
dinucleotide phosphate oxidase) activity, both of which are 
markers of increased oxidative stress.26
Obstructive sleep apnea
Intermittent hypoxia Sympathetic nervous
system activation
Sleep fragmentation
Oxidative stress
HPA axis alterations
inflammatory pathways
adipokine changes
T2DM + prediabetes
Insulin resistance
pancreatic β-cell dysfunction
Figure 1 Links between obstructive sleep apnea and the development of glucose intolerance and T2DM.
Abbreviations: HPA, hypothalamic–pituitary–adrenal axis; T2DM, type 2 diabetes mellitus.
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Autonomic nervous system activation
Activation of the autonomic nervous system occurs in 
association with obstructive apneas and hypopneas; para-
sympathetic activity tends to predominate during apneas; 
and sympathetic tone increases at the termination of apneic 
events. Sympathetic neural drive may be increased at the 
termination of disordered breathing events as a result of 
hypoxia-related activation of peripheral chemoreceptors 
as well as from the effects of sudden arousal from sleep. 
In addition, elevated levels of circulating and urinary cat-
echolamines have been observed in OSA. Interestingly, 
elevated sympathetic tone not only is evident during sleep 
but also seems to persist during the day, even when breathing 
is normal in patients with OSA.27,28
intermittent hypoxia
Another very important pathophysiological feature of OSA 
relates to episodes of intermittent hypoxia and reoxygenation, 
which are associated with disordered breathing events. These 
periods of oxyhemoglobin desaturation and resaturation can 
lead to intermittent tissue hypoxia followed by reoxygenation, 
which has physiologic consequences that differ from those 
of chronic hypoxia. The repetitive decreases and increases 
in oxygen saturation contribute to the formation of reactive 
oxygen and nitrogen species that increase oxidative stress 
and can activate redox-sensitive cellular signaling pathways 
important in inflammation.29–33
To assess the impact of chronic exposure of intermittent 
hypoxia on various physiological parameters, many small 
animal models have been developed. Most of these protocols 
entailed placing rodents in chambers during their sleep periods 
that are flushed with room air (fraction of inspired oxygen 
[FIO
2
] 0.21) followed by different gas mixtures with FIO
2
 
typically at 5% or less with varying cycle times. The resultant 
hypoxemia may be analogous to that which occurs in severe 
human OSA. However, this model has been criticized because 
the extreme reductions in FIO
2
 might lead to hypoxemia that 
is more severe than that seen in mild-to-moderate OSA in 
humans.34 Further, the model is also typically associated with 
hypocapnia, which might not be apparent in OSA in a clinical 
situation. Nevertheless, this model has provided important 
insights, regarding the impact of one of the main pathophysi-
ological features of OSA, namely CIH. CIH in the animal 
model has been shown to activate the proinflammatory tran-
scription factor nuclear factor-κβ (NF-κβ) in cardiovascular 
tissues.35 Activation of NF-κβ has also been demonstrated in 
circulating leukocytes in patients with OSA and is reversible 
with the treatment of OSA.31
In summary, sleep fragmentation, changes in autonomic 
tone, and CIH all have the combined effects of increasing 
sympathetic activation, causing alterations in the HPA axis, 
increasing oxidative stress, and activating inflammatory 
pathways. These in turn can result in insulin resistance 
and pancreatic β-cell dysfunction.21 The impact of CIH on 
overall insulin sensitivity, sympathetic neural activation, and 
organ-specific tissues will be discussed in the subsequent 
sections.
CiH decreases overall insulin sensitivity
Many studies have suggested a link between impaired insulin 
sensitivity and intermittent hypoxemia, which is an important 
component of OSA. Both animal and human data indicate that 
CIH can impair glucose tolerance and clearance and can also 
increase the HOMA index, a marker of insulin resistance.36
In order to mimic the CIH associated with severe OSA, 
an animal study used a model of CIH in mice with exposure 
to CIH during their sleep period, with a return to room air 
conditions for the remainder of the day. Exposure protocols 
ranged from hours to several months. The hyperinsulinemic–
euglycemic clamp technique was then used to assess insulin 
sensitivity during exposure to CIH. The CIH group had a 
21% reduction in the amount of exogenous glucose neces-
sary to maintain euglycemia during the hyperinsulinemic–
euglycemic clamp, indicating that CIH induced insulin 
resistance in these mice. They also exhibited elevated fasting 
glucose, providing strong evidence for a causal relationship 
between exposure to CIH and insulin resistance, independent 
of obesity. Similar findings were also observed in mice with 
diet-induced obesity and genetic obesity.16,36
Human data have subsequently confirmed these findings. 
Exposing healthy human volunteers to a hypoxic alternating 
with normoxic gas mixture (to mimic the CIH often seen with 
patients with moderate sleep apnea) resulted in decreased 
insulin sensitivity without a commensurate increase in 
insulin secretion, indicative of insulin resistance. This study 
also noted a decrease in “glucose effectiveness”: the ability 
of glucose to stimulate its uptake by peripheral tissues and 
to suppress hepatic glucose production independent of an 
insulin response.37
CiH causes sympathetic activation
A potential mechanism linking CIH with peripheral insulin 
resistance is the increased sympathetic neural activity with 
elevation in catecholamines that occurs with exposure to 
CIH.28 These catecholamines both decrease peripheral insu-
lin-mediated glucose uptake and increase insulin resistance.38 
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In addition, activation of the hypothalamic–pituitary–adrenal 
axis impairs insulin sensitivity and also increases mobiliza-
tion of glucose. Animal studies have also assessed the impact 
of CIH-induced sympathetic nervous system activation on 
insulin resistance using a ganglionic blocker (hexametho-
nium) to prevent autonomic activation. However, blockade 
of autonomic activity had no impact on the development of 
insulin resistance in response to CIH. Therefore, mechanisms 
other than sympathetic neural activation seem to be respon-
sible for the development of insulin resistance, at least in 
animal models of CIH. Nevertheless, in a clinical setting, 
overactivation of the sympathetic nervous system, as well 
as the hypothalamic–pituitary–adrenal axis, occurring as a 
result of sleep apnea and its associated sleep fragmentation, 
might contribute to insulin resistance in OSA along with 
other factors.
The effects of CIH on organ- 
specific tissue
CiH and the pancreas
Insulin resistance is an important factor in the pathophysiology 
and evolution of diabetes. However, clinical diabetes develops 
when pancreatic β-cells are unable to compensate for increas-
ing insulin resistance. β-cell dysfunction may lead to impair-
ment of the compensatory increases in insulin secretion that 
are required to maintain normal levels of blood glucose in the 
setting of progressive insulin resistance. Recent data have sug-
gested various mechanisms for pancreatic β-cell dysfunction. 
Lean mice exposed to CIH during their sleep period had 
elevated plasma fasting insulin levels without a change in 
glucose, suggesting the presence of insulin resistance. Despite 
this, there was no compensatory pancreatic β-cell proliferation 
or hypertrophy in these animals. Rather, insulin content was 
decreased in the pancreatic islets due to downregulation of the 
enzyme prohormone convertase 1 that converts proinsulin to 
insulin. Furthermore, the animals exposed to CIH had impaired 
insulin secretion with impairment of insulin synthesis and 
processing in the pancreatic β-cells.39 CIH can also result in 
β-cell apoptosis, through the interaction between apoptosis-
related proteins (Bcl-2 and Bax). CIH-mediated oxidative 
stress results in a downregulation of Bcl-2 and upregulation 
of Bax, and this imbalance promotes apoptosis.40
Additional animal studies have also suggested a possible 
role for mitochondrial-derived ROS in CIH-induced pancre-
atic β-cell injury and dysfunction.39 Finally, cellular studies 
in vitro have demonstrated CIH-induced downregulation of 
CD38 gene expression, which is an important gene involved 
in insulin secretion through the mobilization of Ca2+.41
impact of CiH on the liver
In both animal and human studies, CIH has been shown to 
induce structural liver damage and increase liver enzyme 
levels such as serum alanine aminotransferase, aspartate 
aminotransferase, and alkaline phosphatase.18,19 In animal 
studies, several weeks of CIH exposure resulted in liver ste-
atosis, necrosis, and inflammation with resultant neutrophil 
accumulation and collagen deposits. The mechanisms may 
involve increased synthesis of lipid biosynthesis enzymes, 
proinflammatory cytokines, and oxidative processes, result-
ing in DNA damage and apoptosis.17–19
A study showed that after 5 weeks of CIH, both hypoxia-
inducible factor 1α (HIF-1α) and NF-κβ transcription fac-
tors were upregulated in the liver.42 CIH exposure results in 
increased lipid biosynthesis enzymes in the liver, such as 
sterol regulatory element–binding protein-1 (SREBP-1), 
sterol-coenzyme A desaturase-1 (SCD-1), and high-density 
lipopro tein (HDL) receptor,43 and thus plays an important 
role in the development of NAFLD and the metabolic syn-
drome. CIH also increases the expression of proinflamma-
tory cytokines such as tumor necrosis factor-α (TNF-α) and 
macrophage inflammatory protein 2 in obese mice exposed 
to 4 weeks of CIH. Interestingly, there was no observed 
increase in these cytokines among lean mice.16 Another study 
observed increased liver proinflammatory cytokines such 
as interleukin (IL) 1β, IL-6, and macrophage inflammatory 
protein 2 in lean mice exposed to longer periods of CIH.18 
CIH also results in upregulation of nitric oxide metabolites 
and reduced activity of liver antioxidant enzymes, which can 
contribute to DNA damage and apoptosis.42 In addition, CIH 
can not only increase glucose output from hepatocytes but 
also upregulate gene expression and protein levels of several 
gluconeogenic enzymes in the liver,44 which can contribute 
to fasting hyperglycemia and development of T2DM.
CiH and skeletal muscle
Skeletal muscle is responsible for the majority of insulin-
induced glucose uptake. Despite this, few studies have 
examined the effect of CIH on skeletal muscle metabolism 
and glucose uptake. A study using a mouse model of CIH 
observed not only decreases in whole-body insulin sensitivity 
but also reduces glucose utilization and insulin sensitivity 
in the soleus muscle, suggesting a clear decrease in glucose 
metabolism and uptake in this muscle. The impact of CIH was 
most pronounced in oxidative muscle fibers, while glycolytic 
muscle fibers were relatively unaffected. Thus, glucose uptake 
in oxidative muscle tissue is impaired by CIH and this effect 
appears independent of obesity.45
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CiH and adipose tissue
There have been many recent advances in our understanding 
of the role of white adipose tissue (WAT) in normal physi-
ological function and in response to endogenous stressors.46–48 
WAT not only serves as a reservoir of stored energy in the 
form of triacylglycerols but also serves as an important endo-
crine organ involved in a variety of metabolic activities. It is 
especially important for its role in insulin resistance through 
the release of free fatty acids (FFAs) during lipolysis.49 
These induce insulin resistance through their effects on liver, 
muscle, and adipose tissue itself. CIH can cause dyslipidemia 
through an increased FFA release; interestingly, this effect 
is normalized by oxygen supplementation in humans.50 CIH 
can cause decreased lipoprotein clearance through HIF-1 and 
angiopeoitin-like 4 inhibition of lipoprotein lipase.51 CIH 
also downregulates the potent insulin-sensitizing hormone 
adiponectin in T3-L1 adipocytes. This increases adipose 
tissue production of resistin, which contributes to further 
insulin resistance through inflammatory pathways involving 
cytokines such as TNF-α and IL-6.52
There is also increasing evidence that regions with 
enlarged areas of visceral adipose tissue experience 
hypoxia53,54 as a result of reduced adipose tissue blood 
flow. This occurs as adipocytes hypertrophy and their size 
exceeds the diffusion capacity of oxygen, thus reducing 
regional perfusion of adipose tissue.49 This hypoxic stress 
also activates inflammatory signaling pathways, including 
HIF-1α and NF-κβ.53 OSA in this population can exacer-
bate tissue hypoxia and further contribute to adipose tissue 
inflammation, providing an additional pathway leading to 
insulin resistance and cardiometabolic morbidity. Adipose 
tissue hypoxia also leads to the expression and release of 
various “adipokines”, which are hormones and cytokines that 
have important functions in health and disease. Proinflam-
matory adipokines (including cytokines, chemokines, and 
acute-phase proteins such as haptoglobin and plasminogen 
activator inhibitor 1) play particularly important roles in the 
development of obesity-related insulin resistance. These sub-
stances are associated with obesity-induced proinflammatory 
states and they are elevated in the circulation of obese sub-
jects with insulin resistance, whereas the antiinflammatory 
adipokine, adiponectin, is diminished in the circulation of 
these subjects. As adipocytes increase in size, macrophages 
are attracted to and retained within adipose tissue through 
the actions of chemokines, MCP-1, and MIF, respectively. 
Consequently, infiltration of type M1-macrophages occurs, 
and these in turn secrete the proinflammatory cytokines IL-6 
and TNF-α. Hence, the M1-macrophage arrival in adipose 
 tissues increases the degree of inflammation in already 
inflamed tissues. Such inflammatory processes play a sig-
nificant role in the development of insulin resistance through 
inhibition of adipocyte storage of lipids, secretions of adi-
pokines, enhanced lipolysis, and reduced reesterification of 
FFAs resulting in elevation in FFAs in the circulation.
Potential pathogenic mechanisms 
linking T2DM to OSA
As mentioned previously, there is a higher prevalence of 
OSA in patients with T2DM than in nondiabetic patients. 
This has led to the question of whether a reverse causality 
exists, whereby diabetes itself might lead to some of the 
features of OSA. Potential mechanisms for the association of 
OSA among diabetic populations include altered ventilatory 
control and increased oxidative stress.55,56
Some studies have shown that insulin resistance is asso-
ciated with a reduced hypercapnic and hypoxic ventilatory 
response that is reversed with insulin treatment.57 However, 
it is unclear whether this reduced ventilatory response can 
exacerbate apneas and hypopneas. Yet other studies have 
found an association between diabetes and increased risk of 
central sleep apnea, possibly mediated by autonomic dysfunc-
tion that can in turn cause increased central chemoreceptor 
responsiveness to hypercapnia, thereby predisposing patients 
to periodic breathing and central sleep apnea.11,58–60 Indeed, 
diabetic patients with autonomic neuropathy have a higher 
prevalence of OSA, more severe OSA, longer duration of 
sleep disordered breathing events, and more severe oxygen 
desaturations when compared with diabetic patients without 
autonomic neuropathy.59
Chronic hyperglycemia can also contribute to the devel-
opment of OSA by increasing oxidative stress. This in turn 
can result in structural nerve damage and dysfunction with 
worsening autonomic dysfunction.59
In summary, various possible pathogenic mechanisms 
might contribute to the association of OSA among diabetic 
populations, suggesting that there is a bidirectional relation-
ship between OSA and T2DM.
Continuous positive airway pressure 
therapy in OSA improves glucose 
control
Continuous positive airway pressure (CPAP) is the gold-
standard treatment of OSA and is highly effective in relieving 
the symptoms of OSA. However, its impact on comorbidities, 
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such as diabetes, is less clear with studies demonstrating 
variable effects on markers of insulin resistance and insulin 
sensitivity. A recent meta-analysis of randomized controlled 
studies examining the effects of CPAP on measures of gly-
cemic control suggested that while CPAP does not decrease 
hemoglobin A
1c
 (HbA1c) level or BMI in patients who have 
OSA and T2DM, it may improve insulin sensitivity.61 The 
variable results may be related to differences in methods of 
assessment of insulin sensitivity, variation in study population 
characteristics, and inconsistent adherence to and duration 
of CPAP therapy. Nevertheless, there are data to suggest that 
use of CPAP can increase insulin sensitivity and decrease 
insulin resistance.
CPAP in OSA might improve  
insulin sensitivity
Several studies have suggested that CPAP improves 
insulin sensitivity. An observational study demonstrated 
significant improvement in sensitivity (measured by the 
hyperinsulinemic–euglycemic clamp technique) after 2 days 
and 3 months of CPAP therapy in patients with moderate-to-
severe OSA. Interestingly, this improvement was most pro-
nounced in the subgroup of subjects with a BMI ,30 kg/m2.62 
A meta-analysis of 12 prospective observational studies 
of nondiabetic adults who were newly diagnosed with 
moderate-to-severe OSA demonstrated that CPAP treatment 
for 3–24 weeks resulted in a significant decrease in insulin 
resistance as assessed by HOMA-IR.63
Several other randomized controlled trials have also 
shown significant improvements in insulin sensitivity in 
patients with OSA who are treated with CPAP, compared 
with sham-CPAP. In these studies, insulin sensitivity was 
assessed by the Gutt index, the quantitative insulin sensi-
tivity check index, the short insulin tolerance test, and the 
hyperinsulinemic–euglycemic clamp technique.64–66 One 
such study showed a trend toward improvement in insulin 
sensitivity after CPAP therapy using the hyperinsulinemic–
euglycemic clamp; however, the degree of improvement 
did not reach statistical significance.67 It is possible that the 
failure to obtain a statistically significant result was because 
mean nightly usage of CPAP in that study was only 3.6 hours. 
In another study, nightly CPAP therapy for OSA resulted in a 
significant increase in K
itt
 (glucose disappearance rate) in as 
little as 1 week of nightly use.65 A review and meta-analysis 
by Feng et al obtained information from prospective studies 
examining the effects of CPAP on markers of diabetes in 
patients with OSA and T2DM. Their findings indicate that 
CPAP does not improve BMI or glycemic control (measured 
by HbA1c level) but confirm that it may improve insulin 
sensitivity in patients with OSA and T2DM, as assessed by 
the hyperinsulinemic–euglycemic clamp method.61
The differing methodologies utilized to assess insulin 
sensitivity, patient characteristics, and CPAP adherence rates 
in prior studies may explain some of the variability in their 
results. For example, the quantitative insulin sensitivity check 
index test has a substantially better linear correlation with 
hyperinsulinemic–euglycemic clamp than HOMA-IR and 
performs better in patients with insulin resistance. Likewise, 
HOMA-IR is a good surrogate for the effect of insulin on 
hepatic gluconeogenesis but may not accurately measure 
other facets of insulin response and may be less accurate, 
particularly in the setting of severely impaired pancreatic 
β-cell function.68 Furthermore, OSA, and CPAP treatment 
itself, may alter and interact with various aspects of insulin 
and glucose metabolism such as skeletal muscle insulin 
sensitivity and pancreatic β-cell function that may not be 
adequately assessed by the metrics used in these studies.65
Importantly, a common limitation in most of these trials 
was the limited hours of CPAP use. On average, CPAP use 
ranged from 3.3 hours/night to 6.2 hours/night. In order 
to evaluate the role of increasing hours of usage of CPAP, 
another randomized placebo-controlled study demonstrated 
incremental improvement in the insulin  sensitivity index 
with each additional hour of nightly CPAP use. However, 
in this study, significant improvements in insulin sensi-
tivity were observed only in patients with severe OSA 
(AHI .30/h).66 In order to further assess the impact of 
increased hours of usage, a recent control study random-
ized patients either to receive CPAP 8 hours nightly or to 
receive an oral placebo. Adherence to CPAP was monitored 
with continuous supervision in a sleep laboratory. Glucose 
metabolism was measured with the 2-hour OGTT. In the 
8-hour/night CPAP group, glucose levels were reduced 
and insulin sensitivity was increased when compared to 
placebo. In addition, circulating norepinephrine levels and 
24-hour blood pressure were also reduced in the CPAP 
group as compared to placebo.69 This study highlighted the 
importance of adherence to CPAP therapy when assessing 
its impact on these parameters.
CPAP in OSA improves HbA1c
The percentage of HbA1c, a marker of long-term glucose 
control in diabetic individuals, has been shown to be posi-
tively correlated with the severity of OSA in patients with 
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T2DM. HbA1c increases with the severity of OSA after 
adjusting for age, sex, BMI, race, number of antidiabe-
tes medications, exercise, duration of diabetes, and total 
sleep time compared to patients without OSA.70 A number 
of  studies have shown an improvement in HbA1c after 
3 months of CPAP therapy.71–73 A recent meta-analysis by 
Gallegos et al demonstrated significant improvement in 
HbA1c levels and/or increase in insulin sensitivity with 
.3 months of CPAP therapy among patients who had OSA 
and either prediabetes or T2DM as determined by labora-
tory evaluation.74
Predictably, the magnitude of improvement in HbA1c 
was strongly correlated with the number of hours of nightly 
usage of CPAP.71 In one study, patients who utilized CPAP 
for .4 hours/night (mean 6.6 hours/night) achieved the great-
est improvement in HbA1c.71 In contrast, another investiga-
tion where the mean duration of nightly CPAP use was only 
3.6±2.8 hours/night noted no significant improvements in 
HbA1c or BMI. However, there was significant improvement 
in insulin sensitivity.67
These findings indicate that long-term CPAP therapy 
for OSA may produce significant improvements in glucose 
metabolism and control in T2DM and even prediabetes, but 
adequate nightly adherence to CPAP is essential to achieve 
this outcome.
Impact of therapy for OSA  
on metabolic syndrome
As discussed in a previous section, OSA might be an indepen-
dent risk factor for the development of metabolic syndrome.75 
Elevated systemic arterial hypertension, hyperglycemia, 
hypertriglyceridemia, hypercholesterolemia, abdominal and 
visceral obesity, and insulin resistance are all components of 
metabolic syndrome and have the potential to significantly 
increase the risk of diabetes, cardiovascular, and cerebro-
vascular disease.75
Several studies have explored the effect of CPAP 
therapy for OSA on metabolic syndrome and its specific 
components.64,76,77 The greatest impact of CPAP therapy 
appears to be on systemic arterial pressure. Several random-
ized placebo controlled studies have demonstrated significant 
reductions in arterial blood pressure with CPAP therapy for 
OSA.65,76,78 One such study even showed that systemic arte-
rial pressure significantly increased upon CPAP withdrawal 
among patients with OSA who were previously treated with 
CPAP, providing further evidence for the impact of CPAP 
therapy on hypertension in OSA.78
Hyperlipidemia is another component of metabolic syn-
drome associated with OSA32 and can potentially improve 
with CPAP therapy. Animal models have shown increases in 
serum triglyceride and low-density lipoprotein-cholesterol 
levels with exposure to CIH, possibly through the increased 
activity of SREBP-1 and SCD-1. This increased activity 
enhances conversion of saturated to monounsaturated fatty 
acids, increases serum triglycerides, and promotes lipopro-
tein secretion.79 Another study has shown that lipid profiles 
in patients with OSA can improve with CPAP therapy with 
improvement seen in serum triglycerides, low-density lipo-
protein, nonhigh-density lipoprotein, total cholesterol, and 
the high-density lipoprotein to total cholesterol ratio.65
Abdominal and visceral obesity is another important 
feature of metabolic syndrome linked with increased cardio-
vascular risk in patients with OSA. This has been posited to 
improve with CPAP therapy. However, randomized controlled 
studies of nondiabetic patients with OSA failed to dem-
onstrate a significant impact of CPAP therapy on visceral, 
subcutaneous, or hepatic fat distribution.63,64,80
Despite the contradictory and conflicting nature of some 
of the data, there is mounting evidence that CPAP therapy 
for moderate-to-severe OSA may improve components 
of metabolic syndrome, and this may ultimately reduce 
the cardiovascular and cerebrovascular risk associated 
with OSA.
Treatments other than CPAP are available for OSA. Man-
dibular advancement oral appliance therapy is an effective 
treatment of OSA and has also been shown to improve some 
outcomes related to the metabolic syndrome. Oral appliance 
therapy for OSA has been shown to improve markers of lipid 
peroxidation that are linked to endothelial dysfunction.81 
Markers of endothelial dysfunction, an important event that 
precedes the development of atherosclerosis and might pre-
dict future cardiovascular events, may also improve with oral 
appliance therapy for OSA.82 Some studies have also shown 
improvement in hypertension with this therapeutic modality 
in OSA.83 A parallel group study showed similar reduction in 
morning diastolic blood pressure between CPAP and dental 
appliance therapy after 10 weeks of use.84
The role of weight loss in improving features of the 
metabolic syndrome such as insulin resistance has been 
assessed among patients undergoing bariatric surgery. 
Weight loss following bariatric surgery has been associated 
with improvement in insulin resistance, as well as partial 
or complete remission of T2DM in a subset of patients.85 
However, an independent impact of improved OSA versus 
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weight loss on improvement in manifestations of T2DM has 
not been established.
Clinical implications
Screening for OSA in patients with T2DM
With the increasing prevalence of T2DM and obesity in the 
aging population, there is a growing need to identify those 
patients with T2DM who might also be at risk of OSA, 
since both are independent risk factors for cardiovascular 
and cerebrovascular disease and are often comorbid chronic 
conditions.75 The identification of OSA in patients with 
T2DM is therefore of paramount importance, and this task 
often falls to the primary care physician.
Assessing risk of OSA might be challenging in primary 
care settings because many patients with OSA do not report, 
in routine office visits, “typical” OSA-related symptoms, such 
as heavy snoring, witnessed pauses of breathing during sleep, 
and excessive daytime somnolence. Other risk factors might 
be considered, including anatomic features such as obesity 
(BMI .30 kg/m2), large neck circumference (.16 in for 
females; .17 in for males), a crowded oropharynx with a low 
lying soft palate, large base of tongue and tonsillar hypertrophy, 
as well as craniofacial abnormalities including retrognathia.86 
Evaluation of OSA symptoms should ideally be part of routine 
patient history and physical examinations. However, this might 
not always be practical or feasible, especially in primary care 
settings. Several self-administered screening tools and question-
naires have been developed to facilitate identification of patients 
who may require referral or testing for OSA.
The Epworth Sleepiness Scale is one such tool that 
measures subjectively reported tendency to fall asleep dur-
ing a variety of situations. However, it lacks sensitivity for 
detection of moderate-to-severe OSA. The STOP-Bang 
questionnaire assesses various risk factors for OSA and has 
reasonable sensitivity and specificity when a cutoff score of 
5–8 is used.87,88 However, this tool was specifically developed 
for use in presurgical testing populations. As a result, its 
validation may not apply to primary care or other settings. 
The Berlin questionnaire is another short, ten-question survey 
comprising three different categories. A high risk of OSA is 
identified by positive answers in two or more of the categories, 
which yields a 78.6% sensitivity with a 50.5% specificity, 
for detection of moderate-to-severe OSA.87 The Sleep Apnea 
Clinical Score is a longer questionnaire (36 items) that has 
been validated for calculation of like lihood ratios for the pres-
ence of OSA. A score of $15 yields a likelihood ratio of 4.45 
of moderate–to-severe sleep apnea.89 The  sensitivities and 
specificities of these tools are listed in Table 1.90 The STOP-
Bang questionnaire and the Berlin questionnaire can each 
be completed in ,5 minutes, allowing them to be used as 
effective OSA screening tools in a busy clinical setting. 
Although the sensitivity of the Epworth Sleepiness Scale for 
OSA is relatively low, it can also provide useful data regard-
ing the degree of daytime somnolence and its improvement 
with treatment.
Utilization of these tools in primary care offices might 
aid in raising the suspicion for OSA in diabetic popula-
tions in which the risk is already higher than in the average 
 population. This can ultimately facilitate referral to sleep 
practices where further evaluation for OSA can occur.
Diagnosis of OSA
Once a patient is referred for further sleep evaluation, 
the diagnosis of OSA and its severity can be assessed by 
recording physiologic parameters during sleep. The gold 
standard is attended polysomnography (PSG) performed 
in a sleep laboratory. This comprehensively assesses sleep 
and breathing with recordings of the electroencephalogram, 
electromyogram, electrooculogram, electrocardiogram, 
nasal/oral airflow surrogate, thoracic and abdominal respi-
ratory effort, oxygen saturation, and an audio recording of 
snoring throughout the night.91 Home sleep testing (HST), 
with more limited respiratory assessment, has recently 
gained popularity because of its ease of use and reduced 
cost when compared to standard PSG. This may be useful 
in cases where the pretest probability of moderate or severe 
OSA is high.92,93 However, it must be noted that HST has 
many important limitations that reduce its utility in certain 
settings. It usually only monitors a surrogate for airflow, 
respiratory effort, and oxygen saturation and provides no 
objective measure of total sleep duration or sleep quality. 
This may lead to underestimation of the severity and impact 
Table 1 Predictive value of screening questionnaires for 
moderate-to-severe OSA
Epworth  
Sleepiness  
Scale
STOP-Bang  
questionnaire
Berlin  
questionnaire
Sensitivity (%) 39.0 87.0 78.6
Specificity (%) 71.4 43.3 50.5
Odds ratio  
(95% Ci)
1.6 5.1 3.7
Area under the  
ROC (95% Ci)
0.53 0.64 0.67
Abbreviations: OSA, obstructive sleep apnea; CI, confidence interval; ROC, 
receiver–operating characteristic.
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of sleep disordered breathing, particularly in those patients 
with milder forms of OSA. In addition, automated scoring 
of HST may further  underestimate the severity of OSA 
compared with manual scoring of these studies.94
Patient selection for HST is also important as false-
 negative results may occur in patients with coexisting insom-
nia who might spend a large portion of the test night awake, 
since the AHI is calculated in reference to recording time 
rather that total sleep time, which is usually not measured. 
HSTs are also inadequate for accurate assessment of more 
complex sleep disorders, especially in those patients with 
significant comorbid cardiopulmonary disease. Therefore, 
patients suspected of having OSA on a clinical basis who 
then have negative HST results might need referral for con-
firmatory in-laboratory PSG.93
Treatment of OSA
Various treatment modalities are available for OSA. In order 
to maximize the chances of achieving successful therapeu-
tic outcomes, strong consideration must also be given to 
patient-specific needs, expectations, and comorbidities such 
as cardiac, pulmonary, and cerebrovascular disease, as well 
as to coexisting sleep disorders such as insomnia.
CPAP therapy remains the gold standard for the treatment 
of OSA, with randomized, placebo-controlled trials clearly 
demonstrating significant improvement in quality of life, 
daytime somnolence, and neurobehavioral performance. 
These improvements have been observed for all degrees of 
OSA, including the milder forms.95,96 Several alternatives to 
CPAP therapy can also be considered and include oral appli-
ance therapy for mandibular advancement,97,98 surgeries of the 
upper airway; maxillofacial surgery for jaw advancement,99 
and bariatric surgery for weight loss100 in appropriately 
selected patients. As OSA is a chronic condition, long-term 
disease management with monitoring of compliance and 
treatment efficacy is essential to achieving optimal func-
tional outcomes, as well as for long-term cardiovascular 
risk reduction.101
Conclusion
In summary, there is a high prevalence of insulin resistance 
and T2DM in patients with OSA. An even higher prevalence 
of OSA has been documented in those patients with T2DM 
who are obese. The multiple physiologic disturbances in OSA, 
including sleep fragmentation, activation of the sympathetic 
nervous system, and CIH secondary to recurrent apneas, 
may contribute to abnormal glucose and insulin metabolism. 
CIH, with its associated systemic inflammation and oxidative 
stress, has been demonstrated in animal  models to contribute 
to hepatic and peripheral insulin resistance as well as to pan-
creatic β-cell dysfunction, independent of obesity.
Given the links between T2DM and OSA, screening for 
OSA in this population is important as effective treatment of 
OSA with CPAP may not only improve sleep apnea-related 
symptoms and quality of life but also improve components 
of the metabolic syndrome that contribute to long-term car-
diovascular and cerebrovascular risk.
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